Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.96 USD | -3.09% | -3.01% | -17.42% |
Financials (USD)
Sales 2024 * | 123M | Sales 2025 * | 186M | Capitalization | 2.31B |
---|---|---|---|---|---|
Net income 2024 * | -275M | Net income 2025 * | -159M | EV / Sales 2024 * | 16.6 x |
Net cash position 2024 * | 262M | Net cash position 2025 * | 225M | EV / Sales 2025 * | 11.2 x |
P/E ratio 2024 * |
-8.56
x | P/E ratio 2025 * |
-15.6
x | Employees | 226 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.1% |
Latest transcript on Rhythm Pharmaceuticals, Inc.
1 day | -3.09% | ||
1 week | -3.01% | ||
Current month | -4.53% | ||
1 month | -0.39% | ||
3 months | -22.89% | ||
6 months | +12.24% | ||
Current year | -17.42% |
Managers | Title | Age | Since |
---|---|---|---|
David Meeker
CEO | Chief Executive Officer | 69 | 15-10-31 |
Hunter Smith
DFI | Director of Finance/CFO | 56 | 17-06-30 |
Joseph Shulman
CTO | Chief Tech/Sci/R&D Officer | 49 | 20-07-26 |
Members of the board | Title | Age | Since |
---|---|---|---|
Christophe Jean
BRD | Director/Board Member | 67 | 15-03-31 |
Jennifer Good
BRD | Director/Board Member | 59 | 19-06-18 |
David McGirr
BRD | Director/Board Member | 69 | 15-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.14% | 0 M€ | 0.00% | - | |
0.11% | 0 M€ | 0.00% | - | |
0.09% | 2 M€ | -.--% | ||
0.07% | 1,487 M€ | +9.17% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 37.96 | -3.09% | 750,715 |
24-05-16 | 39.17 | -1.09% | 244,140 |
24-05-15 | 39.6 | -1.93% | 314,629 |
24-05-14 | 40.38 | +0.45% | 283,270 |
24-05-13 | 40.2 | +2.71% | 407,665 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.42% | 2.31B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- RYTM Stock